%0 Journal Article %1 molenaar2018wildtype %A Molenaar, Remco J. %A Maciejewski, Jaroslaw P. %A Wilmink, Johanna W. %A van Noorden, Cornelis J. F. %D 2018 %J Oncogene %K IDH1 IDH2 MUSTREAD cancer-research therapeutic-impact therapy wired %N 15 %P 1949--1960 %R 10.1038/s41388-017-0077-z %T Wild-type and mutated IDH1/2 enzymes and therapy responses %U https://doi.org/10.1038/s41388-017-0077-z %V 37 %X Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of d-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.

@article{molenaar2018wildtype, abstract = {Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of d-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.}, added-at = {2018-12-07T18:05:16.000+0100}, author = {Molenaar, Remco J. and Maciejewski, Jaroslaw P. and Wilmink, Johanna W. and van Noorden, Cornelis J. F.}, biburl = {https://www.bibsonomy.org/bibtex/29259750985a9972c88d2408ef941bae4/marcsaric}, description = {Wild-type and mutated IDH1/2 enzymes and therapy responses | Oncogene}, doi = {10.1038/s41388-017-0077-z}, interhash = {32c24b05a227f19dba2f280a0dc95ad5}, intrahash = {9259750985a9972c88d2408ef941bae4}, issn = {14765594}, journal = {Oncogene}, keywords = {IDH1 IDH2 MUSTREAD cancer-research therapeutic-impact therapy wired}, number = 15, pages = {1949--1960}, refid = {Molenaar2018}, timestamp = {2018-12-07T18:05:16.000+0100}, title = {Wild-type and mutated IDH1/2 enzymes and therapy responses}, url = {https://doi.org/10.1038/s41388-017-0077-z}, volume = 37, year = 2018 }